Oculis Holding AG Overview
Industry: Biotechnology
Sector: Healthcare
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Oculis Holding AG is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Oculis Holding AG in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Oculis Holding AG Competitors
Oculis Holding AG operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans